AMP v. Myriad: A surgical strike on blockbuster business models

Science Translational Medicine

Volumn 5, Issue 192, 2013, Pages

  Gold, E Richard ^a   Cook Deegan, Robert ^b   Bubela, Tania ^c  

^a MCGILL UNIVERSITY   (Canada)

^b DUKE UNIVERSITY   (United States)

^c UNIVERSITY OF ALBERTA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENTARY DNA; DNA; MESSENGER RNA; SYNTHETIC DNA;

BREAST CANCER; CANCER RISK; COMMERCIAL PHENOMENA; EDITORIAL; FINANCIAL MANAGEMENT; GENE MUTATION; GENETIC ANALYSIS; GENETIC DATABASE; GENETIC SCREENING; HEALTH CARE DELIVERY; HEALTH CARE INDUSTRY; HEALTH CARE ORGANIZATION; HEALTH CARE SYSTEM; HUMAN; JURISPRUDENCE; LAW SUIT; MEDICOLEGAL ASPECT; ONCOGENE; OVARY CANCER; PATENT; PATIENT ADVOCACY; PERSONALIZED MEDICINE; PRIORITY JOURNAL; PROFESSIONAL SECRECY; PROTOCOL COMPLIANCE; UNITED STATES;

BIOTECHNOLOGY; COMMERCE; GENETIC TESTING; HUMANS; INDIVIDUALIZED MEDICINE; PATENTS AS TOPIC;

EID: 84880560815     PISSN: 19466234     EISSN: 19466242     Source Type: Journal    
DOI: 10.1126/scitranslmed.3006849     Document Type: Editorial

References (9)

1. SCOTUS blog; www.scotusblog.com/case-fi les/cases/association-for- molecular-pathology-v-myriad-genetics-inc/.
2. G. D. Graff et al., Not quite a myriad of gene patents. Nat. Biotechnol. 31, 404-410 (2013).
3. E. R. Gold, J. Carbone, Myriad Genetics: In the eye of the policy storm. Genet. Med. 12 (suppl.), S39-S70 (2010).
4. J. Carbone et al., DNA patents and diagnostics: Not a pretty picture. Nat. Biotechnol. 28, 784-791 (2010).
5. Department of Health & Human Services, Gene patents and licensing practices and their impact on patient access to genetic tests: Report of the Secretary's advisory committee on Genetics, Health, and Society (2010); http://oba.od.nih.gov/oba/sacghs/reports/sacghs-patents-report- 2010.pdf.
6. J. Richer et al., CCMG statement on gene patents. Clin. Genet. 82, 405-407 (2012).
7. HUGO Intellectual Property Committee, Statement on the scope of gene patents research exemption, and licensing of patented gene sequences for diagnostics (2003); www.hugo-international.org/img/ip-gene-2003.pdf.
8. American College of Medical Genetics, Position statement on gene patents and accessibility of gene testing (1999); www.acmg.net/Static- Content/StaticPages/Gene-Patents.pdf.
9. A. L. Baldwin, R. Cook-Deegan, Constructing narratives of heroism and villainy: Case study of Myriad's BRACAnalysis® compared to Genentech's Herceptin®. Genome Med. 5, 8-21 (2013).